Scarica l'app Stockscreener
23.46
1.76%
-0.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$23.88
Aprire:
$24
Volume 24 ore:
1.03M
Relative Volume:
1.32
Capitalizzazione di mercato:
$1.29B
Reddito:
$199.89M
Utile/perdita netta:
$52.48M
Rapporto P/E:
27.60
EPS:
0.85
Flusso di cassa netto:
$61.15M
1 W Prestazione:
+13.44%
1M Prestazione:
+73.39%
6M Prestazione:
+175.35%
1 anno Prestazione:
+71.12%
Intervallo 1D:
$22.45
$24.60
Intervallo di 1 settimana:
$20.52
$24.60
Portata 52W:
$5.35
$24.60
Stoke Therapeutics Inc Stock (STOK) Company Profile
Nome
Stoke Therapeutics Inc
Settore
Industria
Telefono
781-430-8200
Indirizzo
45 WIGGINS AVENUE, BEDFORD, MA
Confronta STOK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
23.46 | 1.24B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-18 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-03-26 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-07-25 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Ripresa | Canaccord Genuity | Buy |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-10-24 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Iniziato | Jefferies | Buy |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-11-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Iniziato | UBS | Neutral |
| 2021-05-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-12-15 | Ripresa | H.C. Wainwright | Buy |
| 2020-12-11 | Reiterato | Needham | Buy |
| 2020-10-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-09-29 | Iniziato | Needham | Buy |
| 2019-12-18 | Iniziato | Wedbush | Outperform |
| 2019-11-12 | Iniziato | BTIG Research | Buy |
| 2019-10-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-15 | Iniziato | Canaccord Genuity | Buy |
| 2019-07-15 | Iniziato | Cowen | Outperform |
| 2019-07-15 | Iniziato | Credit Suisse | Outperform |
| 2019-07-15 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Siren L.L.C. Buys 247,347 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Sets New 52-Week HighWhat's Next? - MarketBeat
Invesco Ltd. Has $174,000 Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5.4%Time to Sell? - MarketBeat
Granahan Investment Management LLC Buys 92,741 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (STOK) Unveils Promising Data For Dravet Syndrome Drug - Yahoo Finance
Checkpoint Capital L.P. Increases Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Trexquant Investment LP - MarketBeat
Russell Investments Group Ltd. Purchases New Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
What is Stoke Therapeutics Inc.’s valuation compared to sectorShare Buyback & Community Consensus Picks - Lancaster City Council
What’s the analyst consensus on Stoke Therapeutics Inc.New Guidance & Verified Stock Trade Ideas - beatles.ru
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 850 Shares of Stock - MarketBeat
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress - Placera.se
Stoke Therapeutics (NASDAQ:STOK) Reaches New 52-Week HighWhat's Next? - MarketBeat
Stoke Therapeutics stock reaches 52-week high at 20.5 USD By Investing.com - Investing.com Australia
108,087 Shares in Stoke Therapeutics, Inc. $STOK Bought by Nuveen LLC - MarketBeat
Will Stoke Therapeutics Inc. outperform its industry peersJuly 2025 Summary & Stepwise Trade Signal Guides - خودرو بانک
Stoke Therapeutics and the Potential of Zorevunersen in Redefining Dravet Syndrome Treatment - AInvest
Is Stoke Therapeutics Inc. part of any major indexQuarterly Market Review & Fast Moving Stock Trade Plans - خودرو بانک
Why is Stoke Therapeutics Inc. stock going upMarket Growth Review & Technical Entry and Exit Tips - خودرو بانک
Will breakout in Stoke Therapeutics Inc. lead to full recoveryJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
Is Stoke Therapeutics Inc. still worth holding after the dipRisk Management & Technical Pattern Based Buy Signals - Newser
Volume spikes in Stoke Therapeutics Inc. stock – what they mean2025 Trading Volume Trends & AI Driven Stock Price Forecasts - Newser
Analyzing drawdowns of Stoke Therapeutics Inc. with statistical tools2025 Geopolitical Influence & Low Risk Entry Point Tips - Newser
Published on: 2025-09-05 21:40:33 - خودرو بانک
Stoke Therapeutics stock reaches 52-week high at 20.5 USD - Investing.com
Price action breakdown for Stoke Therapeutics Inc.July 2025 Institutional & High Win Rate Trade Tips - Newser
Key metrics from Stoke Therapeutics Inc.’s quarterly data2025 Momentum Check & Expert Verified Movement Alerts - Newser
Applying Wyckoff theory to Stoke Therapeutics Inc. stock2025 Market Overview & Fast Moving Trade Plans - Newser
Relative strength of Stoke Therapeutics Inc. in sector analysisTrade Entry Summary & Entry Point Strategy Guides - Newser
Sector ETF performance correlation with Stoke Therapeutics Inc.Market Rally & Low Drawdown Investment Ideas - Newser
Charles Schwab Investment Management Inc. Sells 31,822 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Market reaction to Stoke Therapeutics Inc.’s recent newsWeekly Gains Report & Entry Point Strategy Guides - Newser
How to use Fibonacci retracement on Stoke Therapeutics Inc.Bull Run & Free Safe Entry Trade Signal Reports - Newser
A | Is Stoke Therapeutics, Inc. a turnaround storyQuarterly Growth Report & Daily Risk Controlled Trade Plans - خودرو بانک
Can volume confirm reversal in Stoke Therapeutics Inc.Weekly Market Outlook & Precise Buy Zone Tips - Newser
What does recent volatility data suggest for Stoke Therapeutics Inc.Portfolio Update Report & Low Risk Investment Opportunities - Newser
Stoke Therapeutics Inc. recovery potential after sell off2025 Market Overview & Risk Managed Investment Entry Signals - Newser
Will Stoke Therapeutics Inc. bounce back from current supportQuarterly Profit Review & Short-Term High Return Ideas - Newser
Insider Sell: Kaye Edward M. MD Sells 61,885 Shares of Stoke The - GuruFocus
Will Stoke Therapeutics Inc. stock go up in YEARJuly 2025 Drop Watch & Consistent Profit Trading Strategies - خودرو بانک
DAFNA Capital Management LLC Buys 272,901 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Institutional scanner results for Stoke Therapeutics Inc.2025 Breakouts & Breakdowns & Verified Momentum Stock Alerts - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Bull Run & Technical Confirmation Trade Alerts - Newser
Stoke Therapeutics' Insider Sales: A Cautionary Tale or a Sign of Strength? - AInvest
Assessing Insider Selling Trends at Stoke Therapeutics (STOK): Liquidity Moves or Loss of Confidence? - AInvest
Stoke Therapeutics Executives Buy and Sell Shares in August and September 2025. - AInvest
Will Stoke Therapeutics Inc. benefit from rate cutsQuarterly Profit Summary & Free Technical Confirmation Trade Alerts - خودرو بانک
What analysts say about Stoke Therapeutics Inc. stockJuly 2025 Sentiment & Precise Swing Trade Entry Alerts - خودرو بانک
Stoke Therapeutics shares fall 2.40% premarket after presenting data from Phase 1/2a and open-label extension studies of zorevunersen. - AInvest
Can a trend reversal in Stoke Therapeutics Inc. lead to recoveryIndex Update & Risk Controlled Swing Trade Alerts - Newser
Stoke Therapeutics Inc Azioni (STOK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):